Iressa efficacy price in India

Detailed information:r, :: >Lung cancer patients all know that targeted drugs for lung cancer include Iressa (gefitinib), Tarceva (erlotinib), afatinib, axitinib, and others. To Reese and others, these targeted drugs have been used in clinical applications, and their effects are well-known. Today, Drug Mail is excerpting a report for readers, hoping to attract everyone's attention. The report states that the liver and kidney cancer targeting drug Nexavar (sorafenib) can improve the survival rate of patients with R mutation-positive lung cancer. The details are as follows:
:r, :: >1. Data published at the European Medical Oncology Conference
:r, :: >A research data at the European Medical Oncology Conference, developed by Bayer (Br) Liver cancer drug Nexavar(r) may be able to improve survival in lung cancer patients who are positive for a specific gene mutation, although it failed to extend survival in studies.
:r , :: >The study, led by teachers from the University Hospital of Seville in Spain, was conducted on lung cancer patients who had failed regular drug treatments. The efficacy of Nexavar was tested in the study. The average survival time in the Nexavar-treated group was days, compared with days in the placebo group.
:r, :: >2. Nexavar can improve the survival rate of lung cancer patients
:r, :: > Bayer of Germany, the R&D company of Nexavar, said in this month.
:r, :: >The study failed to meet its primary goal of extending the lives of patients with advanced lung cancer. But subsequent analysis found that among patients with an R gene mutation, survival rates were twice as high as those on placebo.
:r, :: >The trial failed to meet its primary endpoint, but no further details were disclosed. The company also does not plan to file regulatory filings for Nexavar as a third- or fourth-line treatment for patients with lung cancer.
:r, :: >3. Experts’ comments
:r, :: >Bayer Vice President of Clinical Oncology r said: The company is communicating with the scientific community to discuss the results of the study, and has not yet decided whether to Clinical trials of NEXAVAR are underway in patients with this mutation. r
:r, :: >This may be an accidental discovery, r said in an interview with reporters. These data are provocativec) and at the same time very interesting. In order to answer whether Nexavar or other drugs are effective in patients with R-mutant lung cancer, a prospective trial is indeed needed. But we haven't decided yet. r
:r, :: >This discovery is a major breakthrough and deserves to be verified by prospective studies, RR, an oncologist at the German Hospital in Spain, said in a statement. R was not involved in this study.